Evidence map›Paper›PMID 26822197›Full record

ArticleBMC genetics2016

Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia.

Alexander V Lavrov, Ekaterina Y Chelysheva, Svetlana A Smirnikhina, Oleg A Shukhov, Anna G Turkina, Elmira P Adilgereeva, Sergey I Kutsev

Abstract read
In one paragraph

Article in BMC genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. SNP rs3803264 polymorphisms inFrontiers in aging neuroscience · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexander V LavrovLaboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia. alexandervlavrov@gmail.com.
Ekaterina Y ChelyshevaScientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.
Svetlana A SmirnikhinaLaboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia.
Oleg A ShukhovScientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.
Anna G TurkinaScientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.
Elmira P AdilgereevaLaboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia.
Sergey I KutsevLaboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGenome variability of host genome and cancer cells play critical role in diversity of response to existing therapies and overall success in treating oncological diseases. In chronic myeloid leukemia targeted therapy with tyrosine kinase inhibitors demonstrates high efficacy in most of the patients. However about 15 % of patients demonstrate primary resistance to standard therapy. Whole exome sequencing is a good tool for unbiased search of genetic variations important for prognosis of survival and therapy efficacy in many cancers. We apply this approach to CML patients with optimal response and failure of tyrosine kinase therapy.

resultsWe analyzed exome variations between optimal responders and failures and found 7 variants in cancer-related genes with different genotypes in two groups of patients. Five of them were found in optimal responders: rs11579366, rs1990236, rs176037, rs10653661, rs3803264 and two in failures: rs3099950, rs9471966. These variants were found in genes associated with cancers (ANKRD35, DNAH9, MAGEC1, TOX3) or participating in cancer-related signaling pathways (THSD1, MORN2, PTCRA).

conclusionWe found gene variants which may become early predictors of the therapy outcome and allow development of new early prognostic tests for estimation of therapy efficacy in CML patients. Normal genetic variation may influence therapy efficacy during targeted treatment of cancers.

Indexed as

Polymorphism, Single NucleotideAdultExomeFemaleHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleNeoplasm ProteinsPrognosisNeoplasm Proteins

Identifiers

PMID26822197
PMCPMC4895599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.